Optimal wavelength for the clot waveform analysis : Determination of the best resolution with minimal interference of the reagents
© 2019 John Wiley & Sons Ltd..
INTRODUCTION: Clot waveform analysis (CWA), a new methodology to assess coagulation process, can be usefully applied in various clinical settings. However, its clinical use is limited mainly because of the absence of standardization. No consensus exists regarding the wavelengths at which CWA has to be performed what is crucial for the sensitivity of the CWA.
OBJECTIVES: The primary aim of this study is to determine which wavelength is the most sensitive and specific for CWA. Interindividual baseline absorbance will also be assessed as the impact of reagents from the intrinsic, extrinsic, and common coagulation pathway will be determined.
METHODS: Plasma samples were screened at wavelengths from 280 to 700 nm to provide absorbance spectra in clotted and nonclotted plasma. The interindividual variability of baseline absorbance was obtained by screening plasma from 50 healthy individuals at 340, 635, and 671 nm. The inner-filter effect of reagents was assessed in plasma or serum when appropriate at the same wavelengths. The reagents were those commonly used for activated partial thromboplastin time, prothrombin time, thrombin time, and dilute Russell's viper venom time.
RESULTS: Clotted plasma has higher absorbance value than nonclotted plasma (P < 0.01). The absorbance of all type of samples is higher at 340 nm than at >600 nm (P < 0.01). The interindividual variability at the different wavelengths was around 25%. However, except with the STA®-CKPrest® and STA®-NeoPTimal®, the reagents do not have a significant effect on the baseline absorbance.
CONCLUSIONS: Wavelengths above 650 nm are recommended to perform CWA. Most of the commercialized reagents can be used for CWA.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
International journal of laboratory hematology - 41(2019), 3 vom: 11. Juni, Seite 316-324 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Evrard, Jonathan [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 12.11.2019 Date Revised 12.11.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ijlh.12975 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM293566259 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM293566259 | ||
| 003 | DE-627 | ||
| 005 | 20231225075608.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ijlh.12975 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0978.xml |
| 035 | |a (DE-627)NLM293566259 | ||
| 035 | |a (NLM)30730600 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Evrard, Jonathan |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Optimal wavelength for the clot waveform analysis |b Determination of the best resolution with minimal interference of the reagents |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.11.2019 | ||
| 500 | |a Date Revised 12.11.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 John Wiley & Sons Ltd. | ||
| 520 | |a INTRODUCTION: Clot waveform analysis (CWA), a new methodology to assess coagulation process, can be usefully applied in various clinical settings. However, its clinical use is limited mainly because of the absence of standardization. No consensus exists regarding the wavelengths at which CWA has to be performed what is crucial for the sensitivity of the CWA | ||
| 520 | |a OBJECTIVES: The primary aim of this study is to determine which wavelength is the most sensitive and specific for CWA. Interindividual baseline absorbance will also be assessed as the impact of reagents from the intrinsic, extrinsic, and common coagulation pathway will be determined | ||
| 520 | |a METHODS: Plasma samples were screened at wavelengths from 280 to 700 nm to provide absorbance spectra in clotted and nonclotted plasma. The interindividual variability of baseline absorbance was obtained by screening plasma from 50 healthy individuals at 340, 635, and 671 nm. The inner-filter effect of reagents was assessed in plasma or serum when appropriate at the same wavelengths. The reagents were those commonly used for activated partial thromboplastin time, prothrombin time, thrombin time, and dilute Russell's viper venom time | ||
| 520 | |a RESULTS: Clotted plasma has higher absorbance value than nonclotted plasma (P < 0.01). The absorbance of all type of samples is higher at 340 nm than at >600 nm (P < 0.01). The interindividual variability at the different wavelengths was around 25%. However, except with the STA®-CKPrest® and STA®-NeoPTimal®, the reagents do not have a significant effect on the baseline absorbance | ||
| 520 | |a CONCLUSIONS: Wavelengths above 650 nm are recommended to perform CWA. Most of the commercialized reagents can be used for CWA | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Siriez, Romain |e verfasserin |4 aut | |
| 700 | 1 | |a Morimont, Laure |e verfasserin |4 aut | |
| 700 | 1 | |a Thémans, Pauline |e verfasserin |4 aut | |
| 700 | 1 | |a Laloy, Julie |e verfasserin |4 aut | |
| 700 | 1 | |a Bouvy, Céline |e verfasserin |4 aut | |
| 700 | 1 | |a Gheldof, Damien |e verfasserin |4 aut | |
| 700 | 1 | |a Mullier, François |e verfasserin |4 aut | |
| 700 | 1 | |a Dogné, Jean-Michel |e verfasserin |4 aut | |
| 700 | 1 | |a Douxfils, Jonathan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of laboratory hematology |d 2007 |g 41(2019), 3 vom: 11. Juni, Seite 316-324 |w (DE-627)NLM167703048 |x 1751-553X |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2019 |g number:3 |g day:11 |g month:06 |g pages:316-324 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ijlh.12975 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2019 |e 3 |b 11 |c 06 |h 316-324 | ||